An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform
An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform
复制标题
DOI：
10.1002/anie.200602251
复制
发表时间：
2006-01-01
影响因子：
16.6
通讯作者：
Jon, Sangyong
中科院分区：
文献类型：
--
作者：
Bagalkot, Vaishali;Farokhzad, Omid C.;Jon, Sangyong
特洛伊适体：通过在多柔比星（Dox）和结合前列腺特异性膜抗原（PSMA）的A10 RNA适体之间形成物理缀合物（参见方案），开发了用于靶向药物递送至癌细胞的新策略。适体-Dox缀合物可以有效地结合至PSMA表达细胞，从而导致其摄取和Dox的细胞内释放。（图为）。
Trojan aptamer: A novel strategy for targeted drug delivery to cancer cells was developed through the formation of a physical conjugate (see scheme) between doxorubicin (Dox) and the A10 RNA aptamer that binds to the prostate-specific membrane antigen (PSMA). The aptamer-Dox conjugate could efficiently bind to PSMA-expressing cells, thereby resulting in its uptake and the intracellular release of Dox.(Figure Presented).